Extension Study of IONIS-GHR-LRx Administered to Participants With Acromegaly Being Treated With Long-acting Somatostatin Receptor Ligands

计划入组 39 人 · 首次发布于 2019 年 5 月 30 日

Safety, Tolerability, and Efficacy of IONIS-GHR-LRx in Participants With Acromegaly Being Treated With Long-acting Somatostatin Receptor Ligands

计划入组 43 人 · 首次发布于 2018 年 6 月 7 日

A Randomized, Controlled, Multi-Center Study to Evaluate the Safety and Efficacy of Paltusotine in Subjects with Acromegaly Treated with Long-acting Somatostatin Receptor Ligands.

计划入组 1 人

Somatostatin

C₇₆H₁₀₄N₁₈O₁₉S₂ · Rx

Estrogen receptor ligands(Naprogenix)

nociceptin receptor ligands (Novo Nordisk)

Arvinas Estrogen Receptor, Inc.

United States

Arvinas Androgen Receptor, Inc.

United States

Crinetics

United States

FDA Sets Q3 2025 Approval Dates for Three Breakthrough Therapies Targeting Rare Diseases

Oral Paltusotine Demonstrates Efficacy in Phase 3 Acromegaly Trial, Offering Alternative to Injectable Treatments

FDA Accepts Crinetics' Paltusotine NDA for Acromegaly Treatment